IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v20y2023i23p7107-d1286731.html
   My bibliography  Save this article

The Dutch Pregnancy Drug Register: Suitable to Study Paternal Drug Exposures?

Author

Listed:
  • Annerose E. van der Mijle

    (Netherlands Pharmacovigilance Centre Lareb, 5237 MH Hertogenbosch, The Netherlands)

  • Petra J. Woestenberg

    (Netherlands Pharmacovigilance Centre Lareb, 5237 MH Hertogenbosch, The Netherlands)

  • Leanne J. Kosse

    (Netherlands Pharmacovigilance Centre Lareb, 5237 MH Hertogenbosch, The Netherlands)

  • Eugène P. van Puijenbroek

    (Netherlands Pharmacovigilance Centre Lareb, 5237 MH Hertogenbosch, The Netherlands
    Groningen Research Institute of Pharmacy, PharmacoTherapy—Epidemiology & Economics, University of Groningen, 9713 AV Groningen, The Netherlands)

Abstract

Paternal medication use around the time of conception is common, but information about its effects on pregnancy outcome and the health of the child is generally limited. The aim of this study is to examine the feasibility of studying paternal exposure in the Dutch Pregnancy Drug Register by using immunosuppressants as a proof of concept. In 113 of 15,959 pregnancies, long-term paternal immunosuppressant use was reported 3 months before conception. In total, 134 immunosuppressants were used. Pregnancy outcome was known for 54 cases and was in accordance with previous findings. Two spontaneous abortions, two premature births, six small for gestational age babies, and two major congenital malformations were reported. Time to pregnancy (TTP) was known for 9548 pregnancies, including 89 with paternal immunosuppressant use. TTP analysis did not show a difference in pregnancies with paternal immunosuppressant use compared to the control group. Moreover, the number of fertility treatments in the paternal immunosuppressant group was similar to the control group. In our opinion, it is feasible to use the Dutch Pregnancy Drug Register to study the effects of paternal exposure on pregnancy outcome. However, to study the potential effects on fertility, more information is needed, particularly since the beginning of pregnancy attempts.

Suggested Citation

  • Annerose E. van der Mijle & Petra J. Woestenberg & Leanne J. Kosse & Eugène P. van Puijenbroek, 2023. "The Dutch Pregnancy Drug Register: Suitable to Study Paternal Drug Exposures?," IJERPH, MDPI, vol. 20(23), pages 1-9, November.
    • Handle: RePEc:gam:jijerp:v:20:y:2023:i:23:p:7107-:d:1286731
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/20/23/7107/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/20/23/7107/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Saskia Vorstenbosch & Bernke Winkel & Marleen M. H. J Gelder & Agnes Kant & Nel Roeleveld & Eugène Puijenbroek, 2019. "Aim and Design of pREGnant, the Dutch Pregnancy Drug Register," Drug Safety, Springer, vol. 42(1), pages 1-12, January.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jonathan L. Richardson & Alan Moore & Rebecca L. Bromley & Michael Stellfeld & Yvonne Geissbühler & Matthew Bluett-Duncan & Ursula Winterfeld & Guillaume Favre & Amalia Alexe & Alison M. Oliver & Yrea, 2023. "Core Data Elements for Pregnancy Pharmacovigilance Studies Using Primary Source Data Collection Methods: Recommendations from the IMI ConcePTION Project," Drug Safety, Springer, vol. 46(5), pages 479-491, May.
    2. Michael Ceulemans & Kristel Van Calsteren & Karel Allegaert & Veerle Foulon, 2022. "Information Needs and Counseling Preferences among Potential Users of the Future Teratology Information Service in Belgium: A Cross-Sectional Study Involving the Public and Healthcare Professionals," IJERPH, MDPI, vol. 19(14), pages 1-14, July.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:20:y:2023:i:23:p:7107-:d:1286731. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.